Enoxaparin Market Size, Share, and Industry Analysis By Application (Deep Vein Thrombosis & Pulmonary Embolism, Heart Attack, and Others), By End User (Hospitals & ASCs, Clinics, and Others), and Regional Forecast, 2024-2032

Enoxaparin sodium is a low molecular weight heparin (LMWH) product, which is available as an injectable medicine that helps the prevention of blood clot formation in the body. Additionally, enoxaparin is indicated in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or patients with severely restricted mobility during acute illness. Furthermore, enoxaparin is used for inpatient and outpatient treatment of DVT with or without pulmonary embolism and in the treatment of patients suffering from other cardiovascular diseases. Thus, the rise in the prevalence of blood clotting diseases and cardiovascular diseases is anticipated to drive the demand for enoxaparin injection, boosting the market growth.

• For instance, according to an article published in May 2021, it was reported that venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a chronic disease that affects approximately 10 million people every year worldwide.

In addition, enoxaparin is used in patients who are on bedrest or who are having a hip replacement, knee replacement, or stomach surgery as prophylaxis for the prevention of blood clots in the leg. Thus, a rise in the number of individuals undergoing hip and knee replacement surgeries is anticipated to boost the demand for enoxaparin, driving the growth of the market.

• For instance, as per data published by the American College of Rheumatology in February 2023, around 790,000 total knee replacement surgeries and above 450,000 hip replacement surgeries are performed annually in the U.S.

Furthermore, the strong focus of key players toward the adoption of various strategic initiatives such as innovative product launches, collaborations & partnerships, and others is also expected to drive the market growth over the forecast period. 

• For instance, in August 2021, Zydus Pharmaceuticals Inc., USA, and CHEMI SpA of Italy signed a license and supply agreement to launch the generic equivalent of Sanofi Aventis’s Lovenox (Enoxaparin Sodium Injection) in seven dosage strengths in the U.S.

However, adverse reactions associated with the enoxaparin administration, such as bleeding gums, coughing up blood, difficulty with breathing or swallowing, dizziness, headache, and bruising, are expected to hamper the market growth to a certain extent.

The COVID-19 pandemic has had a positive impact on the global enoxaparin market due to a rise in the incidence of pulmonary embolism, and deep vein thrombosis in individuals suffering from COVID-19 infection. This factor boosted the demand for enoxaparin in the pandemic period. For instance, as per  data published by the Radiological Society of North America, in December 2020, around 16.5% of the patient population with coronavirus disease 2019 (COVID-19) were suffering from pulmonary embolism (PE) and 14.8% patient of COVID-19 were suffering from deep vein thrombosis (DVT).

Key Insights

The report covers the following key insights:

• Prevalence of Key Cardiovascular Diseases - by Key Countries/Regions, 2022/2023


• Number of Key Surgeries - by Key Countries/Regions, 2022/2023


• Blood Clots: Stats & Facts


• Regulatory Scenario, by Key Countries/ Region


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Impact of COVID-19 on the Market

Segmentation

Analysis by Application

Based on application, the deep vein thrombosis & pulmonary embolism segment accounted for a significant proportion of the global enoxaparin market in 2023. The growth was mainly attributed to the increase in the prevalence of deep vein thrombosis & pulmonary embolism and the high adoption of enoxaparin for the treatment of these clotting diseases.

• For instance, according to a report published by the Centers for Disease Control and Prevention in June 2023, the number of people suffering from venous thromboembolism (VTE) in the U.S. ranges between 350,000 and 900,000 per year. Further, the estimated number of people who die each year from blood clots is from 100,000 to 300,000.

Regional Analysis

North America dominated the enoxaparin market in 2023 and is projected to maintain its position over the forecast period. The growth of North America is mainly due to an increase in the prevalence of cardiovascular diseases such as myocardial infarction, pulmonary embolism, and others, and the increase in the adoption of enoxaparin for the prevention of ischemic complications such as heart attack. Additionally, strong presence of well-established market players in the region also supports the regional market growth.

• For instance, as per data published by the Center for Disease Control and Prevention (CDC) in May 2023, about 805,000 people in the U.S. have had a heart attack. Of these, 605,000 had a first heart attack and 200,000 happened to be people who have already had a heart attack.

In addition, rising number of surgical procedures such as abdominal surgery, hip replacement, and knee replacement and the soaring focus on research and development by market players are driving the growth of the market in North America.

In Asia Pacific, the market for enoxaparin is expected to grow at a significant rate over the forecast period. Factors such as a large patient base with high unmet medical needs, improving healthcare infrastructure in developing countries, and increasing awareness regarding cardiovascular health are anticipated to drive the market growth during the forecast period.

Key Players Covered

The report includes the profiles of key players such as Sanofi, Teva Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Sandoz, Taj Pharma, Chengdu Baiyu Pharmaceutical Co., Ltd., CiplaMed, Techdow Pharmaceutical, Amphastar Pharmaceuticals, and Northstar LLC.

Key Industry Developments

• In August 2023, Venus Remedies, an Indian pharmaceutical company, achieved a significant milestone by securing marketing approval for its enoxaparin prefilled syringes in the Kingdom of Saudi Arabia.


• In July 2023, Rovi launched its Enoxaparin biosimilar in Jordan and Sri Lanka. It will continue international expansion in other markets with strong growth potential through licensing agreements.


• In March 2023, Techdow USA Inc. received the U.S. FDA approval for its enoxaparin sodium products available in the pre-filled syringes form for the U.S. market.